Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Author Archives: Mission IR

Cardium Therapeutics Inc. (CXM) Presents Fourth Quarter and Year-End 2011 Financial Results and Recent Developments

Posted on March 30, 2012 by Mission IR

Cardium Therapeutics today presented highlights of financial results for its fourth quarter and fiscal year ended December 31, 2011, and other recent developments and outlook for 2012. (Logo: http://photos.prnewswire.com/prnh/20051018/CARDIUMLOGO) Highlights of 2011 and Recent Developments Initiated market introduction of Cardium’s new Excellagen™ … Continue reading →

Posted in Cardium Therapeutics Inc. CXM | Leave a comment

Cardium Therapeutics Inc. (CXM) Announces U.S. Market Introduction of Excellagen™; Also Announces Smith Medical Partners as Logistics Partner for National Distribution of Excellagen™

Posted on March 30, 2012 by Mission IR

Cardium Therapeutics today announced market introduction of its Excellagen™ professional-use, syringe-based wound care product for the management of diabetic foot ulcers, pressure ulcers and other dermal wounds. (Photo:  http://photos.prnewswire.com/prnh/20120330/LA79308) (Logo:  http://photos.prnewswire.com/prnh/20051018/CARDIUMLOGO) Excellagen is a new, FDA-cleared highly-refined fibrillar collagen-based topical … Continue reading →

Posted in Cardium Therapeutics Inc. CXM | Leave a comment

RevNutrition.com to Carry MedPodium Nutra-Apps® Brand

Posted on March 21, 2012 by Mission IR

Nutritional Products International (NPI) and Cardium Therapeutics today announced that MedPodium Nutra-Apps® products are now available on RevNutrition.com. (Logo: http://photos.prnewswire.com/prnh/20051018/CARDIUMLOGO) The MedPodium Nutra-Apps brand offers easy-to-use dietary supplements that have been formulated to promote personal health and wellness for today’s … Continue reading →

Posted in Cardium Therapeutics Inc. CXM | Leave a comment

Cardium Therapeuttics Inc. (CXM) Initiates Generx® Phase 3 Clinical Registration Study

Posted on March 20, 2012 by Mission IR

Cardium Therapeutics today announced the initiation of the ASPIRE Phase 3 registration study to evaluate the therapeutic effects of Cardium’s lead product candidate, Generx® (Ad5FGF-4) in patients with myocardial ischemia (insufficient blood flow in the heart due to coronary artery … Continue reading →

Posted in Cardium Therapeutics Inc. CXM | Leave a comment

Cardium Therapeutics Inc. (CXM) Partners With NPI, InHealth Media

Posted on March 14, 2012 by Mission IR

Cardium Therapeutics  is now making its MedPodium Nutra-Apps® products available across the United States by working with Nutritional Products International (NPI) and InHealth Media. (Logo: http://photos.prnewswire.com/prnh/20051018/CARDIUMLOGO) Nutra-Apps are easy-to-use dietary supplements designed to promote personal health and well being for … Continue reading →

Posted in Cardium Therapeutics Inc. CXM | Leave a comment

Uranium Energy Corp (UEC) Reports Fiscal 2012 Q2 Production Results and Provides Operations Update

Posted on March 12, 2012 by Mission IR

Uranium Energy is pleased to report financial and production results for the second quarter ended January 31, 2012.  Major second quarter highlights include the following: Completion of First Full Year of Production: This quarter marked the completion of the first … Continue reading →

Posted in Uranium Energy Corp. UEC | Leave a comment

Uranium Energy Corp (UEC) Announces an Inferred Resource of 5.5 Million Pounds U3O8 at the Company’s Workman Creek Project in Arizona

Posted on March 6, 2012 by Mission IR

Uranium Energy is pleased to announce that the Company has received an independent National Instrument 43-101 Technical Report for its Workman Creek Project located in Gila County, Arizona, that reports an inferred mineral resource of 3,222,000 tons containing 5,542,000 lbs. … Continue reading →

Posted in Uranium Energy Corp. UEC | Leave a comment

Investor Optimism in Biotech Skyrockets – Cardium Therapeutics Inc. (CXM) and Oncothyreon on the Upswing

Posted on February 23, 2012 by Mission IR

Biotechnology stocks have performed well of late as companies from across the globe earn more investments. According to a report from Boulder-based data company OnBioVC, biotech companies attracted close to double the amount of investment in the fourth quarter of … Continue reading →

Posted in Cardium Therapeutics Inc. CXM | Leave a comment

Cardium Therapeutics Inc. (CXM) Announces Closing of $5.0 Million Equity Financing

Posted on February 16, 2012 by Mission IR

Cardium Therapeutics today announced that it has completed the previously announced sale of 17,857,143 shares of its common stock in a registered direct offering for gross proceeds of approximately $5.0 million, before deducting placement agent’s fees and estimated offering expenses. … Continue reading →

Posted in Cardium Therapeutics Inc. CXM | Leave a comment

Uranium Stocks on the Upswing as Chinese Nuclear Demand Grows

Posted on February 14, 2012 by Mission IR

Uranium stocks have performed well in 2012. The Global X Uranium ETF — the first ETF to track companies involved in uranium mining — is up more than 20 percent this year after collapsing more than 50 percent in 2011 … Continue reading →

Posted in Uranium Energy Corp. UEC | Leave a comment